Affiliation:
1. Departments of Pathology
2. Epidemiology, University of Iowa College of Medicine, and College of Public Health, Iowa City, Iowa 52242
3. The Jones Group/JMI Laboratories, North Liberty, Iowa 52317
4. Medicine
Abstract
ABSTRACT
The in vitro activities of ravuconazole and voriconazole were compared with those of amphotericin B, flucytosine (5FC), itraconazole, and fluconazole against 6,970 isolates of
Candida
spp. obtained from over 200 medical centers worldwide. Both ravuconazole and voriconazole were very active against all
Candida
spp. (MIC at which 90% of the isolates tested are inhibited [MIC
90
], 0.25 μg/ml; 98% of MICs were ≤1 μg/ml); however, a decrease in the activities of both of these agents was noted among isolates that were susceptible-dose dependent (fluconazole MIC, 16 to 32 μg/ml) and resistant (MIC, ≥ 64 μg/ml) to fluconazole.
Candida albicans
was the most susceptible species (MIC
90
of both ravuconazole and voriconazole, 0.03 μg/ml), and
C. glabrata
was the least susceptible species (MIC
90
, 1 to 2 μg/ml). Ravuconazole and voriconazole were each more active in vitro than amphotericin B, 5FC, itraconazole, and fluconazole against all
Candida
spp. and were the only agents with good in vitro activity against
C. krusei
. These results provide further evidence for the spectrum and potency of ravuconazole and voriconazole against a large and geographically diverse collection of
Candida
spp.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
210 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献